• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一种以红细胞作为生物反应器给药2',3'-二脱氧胞苷的非线性三室模型。

A nonlinear three-compartment model for the administration of 2',3'-dideoxycytidine by using red blood cells as bioreactors.

作者信息

Solimano F, Bischi G I, Bianchi M, Rossi L, Magnani M

机构信息

Istituto di Biomatematica, Universita' di Urbino, Italy.

出版信息

Bull Math Biol. 1990;52(6):785-96. doi: 10.1007/BF02460809.

DOI:10.1007/BF02460809
PMID:2177675
Abstract

A non-linear three-compartment model is proposed to describe a new strategy for the administration of 2',3'-dideoxycytidine (ddCyd) in the treatment of HIV infections. The drug is injected after having been encapsulated in a non-diffusible form (ddCMP) into erythrocytes. Numerical solutions show that by this treatment the highest ddCyd blood concentration is strongly reduced and in turn its toxicity, while long-lasting therapeutic effect is assured. The model is compared with experimental data in vitro.

摘要

提出了一种非线性三室模型来描述2',3'-双脱氧胞苷（ddCyd）治疗HIV感染的新给药策略。该药物以不可扩散的形式（ddCMP）封装在红细胞中后进行注射。数值解表明，通过这种治疗，ddCyd的最高血药浓度会大幅降低，进而降低其毒性，同时确保长期的治疗效果。将该模型与体外实验数据进行了比较。

相似文献

1
A nonlinear three-compartment model for the administration of 2',3'-dideoxycytidine by using red blood cells as bioreactors.一种以红细胞作为生物反应器给药2',3'-二脱氧胞苷的非线性三室模型。
Bull Math Biol. 1990;52(6):785-96. doi: 10.1007/BF02460809.
2
Human red blood cells as bioreactors for the release of 2',3'-dideoxycytidine, an inhibitor of HIV infectivity.人类红细胞作为用于释放2',3'-二脱氧胞苷（一种HIV感染性抑制剂）的生物反应器。
Biochem Biophys Res Commun. 1989 Oct 16;164(1):446-52. doi: 10.1016/0006-291x(89)91740-3.
3
An optimal time control problem for the administration of 2',3'-dideoxycytidine by using red blood cells as bioreactors.以红细胞作为生物反应器给药2',3'-二脱氧胞苷的最优时间控制问题。
Bull Math Biol. 1993;55(4):715-30. doi: 10.1007/BF02460670.
4
In vitro toxicity and metabolism of 2',3'-dideoxycytidine, an inhibitor of human immunodeficiency virus infectivity.2',3'-双脱氧胞苷（一种人类免疫缺陷病毒感染性抑制剂）的体外毒性与代谢
Chem Biol Interact. 1991;79(1):53-64. doi: 10.1016/0009-2797(91)90052-9.
5
An optimal control problem for the administration of a drug by using red blood cells as bioreactors.一个将红细胞用作生物反应器来给药的最优控制问题。
Adv Exp Med Biol. 1992;326:247-53. doi: 10.1007/978-1-4615-3030-5_31.
6
2',3'-dideoxycytidine permeation of the human erythrocyte membrane.2',3'-双脱氧胞苷对人红细胞膜的渗透作用。
Biochem Int. 1989 Aug;19(2):227-34.
7
Treatment of woodchuck hepatitis virus infection in vivo with 2', -3'-dideoxycytidine (ddC) and 2',-3'-dideoxycytidine monophosphate coupled to lactosaminated human serum albumin (L-HSA ddCMP).
Liver. 1996 Apr;16(2):88-93. doi: 10.1111/j.1600-0676.1996.tb00710.x.
8
2',3'-Dideoxycytidine toxicity in cultured human CEM T lymphoblasts: effects of combination with 3'-azido-3'-deoxythymidine and thymidine.2',3'-二脱氧胞苷对培养的人CEM T淋巴母细胞的毒性：与3'-叠氮-3'-脱氧胸苷和胸苷联合使用的效果
Mol Pharmacol. 1990 Aug;38(2):237-43.
9
In vitro and in vivo toxicity of 2',3'-dideoxycytidine in mice.2',3'-二脱氧胞苷对小鼠的体外和体内毒性
Chem Biol Interact. 1992 Dec;85(2-3):255-63. doi: 10.1016/0009-2797(92)90066-t.
10
Dideoxycytidine permeation and salvage by mouse leukemia cells and human erythrocytes.
Biochem Pharmacol. 1989 Oct 15;38(20):3469-75. doi: 10.1016/0006-2952(89)90116-0.

引用本文的文献

1
An optimal time control problem for the administration of 2',3'-dideoxycytidine by using red blood cells as bioreactors.以红细胞作为生物反应器给药2',3'-二脱氧胞苷的最优时间控制问题。
Bull Math Biol. 1993;55(4):715-30. doi: 10.1007/BF02460670.

本文引用的文献

1
Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides.2',3'-双脱氧核苷对人III型嗜T淋巴细胞病毒/淋巴结病相关病毒（HTLV-III/LAV）体外感染性及细胞病变效应的抑制作用
Proc Natl Acad Sci U S A. 1986 Mar;83(6):1911-5. doi: 10.1073/pnas.83.6.1911.
2
Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT).2',3'-二脱氧胞苷作为单一药物及与齐多夫定（AZT）交替使用治疗严重人类免疫缺陷病毒感染的I期研究。
Lancet. 1988 Jan 16;1(8577):76-81. doi: 10.1016/s0140-6736(88)90283-8.
3
2',3'-dideoxycytidine permeation of the human erythrocyte membrane.
2',3'-双脱氧胞苷对人红细胞膜的渗透作用。
Biochem Int. 1989 Aug;19(2):227-34.
4
Human red blood cells as bioreactors for the release of 2',3'-dideoxycytidine, an inhibitor of HIV infectivity.人类红细胞作为用于释放2',3'-二脱氧胞苷（一种HIV感染性抑制剂）的生物反应器。
Biochem Biophys Res Commun. 1989 Oct 16;164(1):446-52. doi: 10.1016/0006-291x(89)91740-3.
5
Reversed-phase liquid chromatographic determination of 2',3'-dideoxycytidine in human blood samples.反相液相色谱法测定人血样中的2',3'-二脱氧胞苷
J Chromatogr. 1989 Jun 30;491(1):215-20. doi: 10.1016/s0378-4347(00)82835-2.
6
Strategies for antiviral therapy in AIDS.艾滋病抗病毒治疗策略。
Nature. 1987;325(6107):773-8. doi: 10.1038/325773a0.